ACE Inhibitor Combined with Spironolactone in the Treatment of Non Adenoma Primary Hyperaldosteronism
Objective: To investigate the clinical effect of ACE inhibitor (ACEI) combined with Spironolactone in the treatment of non adenoma primary Hyperaldosteronism (PA). Methods: 80 patients who entered our hospital from August 2021 to August 2022 were randomly selected for this investigation. According to the random grouping method, the patients were randomly divided into the observation group and the control group. A total of 40 patients in the control group were treated with Spironolactone. A total of 40 patients in the observation group were treated with perindopril on the basis of the control group. After treatment in different ways, the treatment efficiency of the two groups was compared, The left ventricular end diastolic diameter (LVEDD), left ventricular Ejection fraction (LVEF) and left ventricular end systolic diameter (LVESD) before and after treatment were compared between the two groups, and the incidence of adverse reactions after treatment was compared between the two groups. Result: The effective rate of treatment in the observation group was 95%, significantly higher than 78% in the control group. The difference between the two groups was significant and statistically significant (p<0.05). Before treatment, there was no significant difference in LVEDD, LVEF, and LVESD between the two groups (p>0.05). After treatment, the LVEF of both groups of patients increased, but the observation group was significantly higher than the control group, and the LVEDD and LVESD of both groups of patients were significantly reduced, but the observation group was significantly lower than the control group, The difference between the two groups was significant and statistically significant (p<0.05). The incidence of adverse reactions in the observation group was 12.5%, while the incidence of adverse reactions in the control group was 15%. There was no significant difference between the two groups and there was no statistically significant difference (P>0.05). Conclusion: The combination of Spironolactone and ACEI in PA patients has a more significant effect, can significantly improve the treatment efficiency of patients, improve the cardiac function indicators of patients more significantly, and will not increase additional adverse reactions. It has clinical value.
Guo JH. Observation on the efficacy of ACE inhibitor combined with Spironolactone in the treatment of non adenoma primary Hyperaldosteronism [J]. Medical Theory and Practice, 2020,33 (19): 3208-3209.
Li BB, Tian Y, Liu DK, Chu QF. The efficacy of benazepril combined with Spironolactone in the treatment of non adenoma PA patients [J]. Journal of Heze Medical specialty, 2021,33 (04): 9-12.
Tan XQ, Huang GQ. The efficacy of Nifedipine sustained-release tablets combined with Spironolactone in the treatment of primary Hyperaldosteronism [J]. Practical Clinical Integrated Traditional and Western Medicine, 2021, 21 (21): 134- 135+143.
Wang F, Ren HQ, Shen XB, et al Clinical efficacy of perindopril combined with Spironolactone in the treatment of non adenoma primary Hyperaldosteronism [J] Progress in Modern Biomedical Sciences, 2018,18 (7): 1302-1305.
Copyright (c) 2023 Hua Chen, Junlong Wu, Zhaoshan Ji
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.